Upregulation of PAX2 promotes the metastasis of esophageal cancer through interleukin-5

Cellular Physiology and Biochemistry

Volumn 35, Issue 2, 2015, Pages 740-754

  Liu, Pengfei ^a   Gao, Yi ^a   Huan, Jian ^b   Ge, Xin ^c   Tang, Yiting ^c   Shen, Wenhao ^c   Tian, Ye ^c   Shen, Weidong ^a   Zou, Shitao ^d   Zhou, Jundong ^d   Zhang, Shuyu ^c  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Esophageal squamous cell carcinoma (ESCC); Interleukin 5 (IL 5); Metastasis; Paired box gene 2 (PAX2)

Indexed keywords

INTERLEUKIN 5; MESSENGER RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PAX2; IL5 PROTEIN, HUMAN; PAX2 PROTEIN, HUMAN;

ADULT; ARTICLE; BINDING SITE; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; AGED; CELL MOTION; CELL SURVIVAL; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-5; MALE; MIDDLE AGED; PAX2 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84921876348     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369734     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Rice TW, Blackstone EH: pT2N0M0 esophageal squamous cell cancer: location, grade, and statistics. J Thorac Cardiovasc Surg 2013; 145: 1426-1427.
3. Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 2003; 349: 2241-2252.
4. D'Amico TA: Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res 2007; 1: 188-196.
5. Nebert DW: Transcription factors and cancer: an overview. Toxicology 2002; 181: 131-141.
6. Libermann TA, Zerbini LF: Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006; 6; 17-33.
7. Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, Kumar P: Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 2008; 12: 2281-2294.
8. Maulbecker CC, Gruss P: The oncogenic potential of Pax genes. Embo J 1993; 12: 2361-2367.
9. Bouchard M, Grote D, Craven SE, Sun Q, Steinlein P, Busslinger M: Identification of Pax2-regulated genes by expression profiling of the mid-hindbrain organizer region. Development 2005; 132: 2633-2643.
10. Torres M, Gomez-Pardo E, Dressler GR, Gruss P: Pax-2 controls multiple steps of urogenital development. Development 1995; 121: 4057-4065.
11. Torban E, Eccles MR, Favor J, Goodyer PR: PAX2 suppresses apoptosis in renal collecting duct cells. Am J Pathol 2000; 157: 833-842.
12. Sanyanusin P, Schimmenti LA, McNoe LA, Ward TA, Pierpont ME, Sullivan MJ, Dobyns WB, Eccles MR: Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat Genet 1995; 9: 358-364.
13. Martinovic-Bouriel J, Benachi A, Bonniere M, Brahimi N, Esculpavit C, Morichon N, Vekemans M, Antignac C, Salomon R, Encha-Razavi F, Attié-Bitach T, Gubler MC: PAX2 mutations in fetal renal hypodysplasia. Am J Med Genet A 2010; 152: 830-835.
14. Igarashi T, Ueda T, Suzuki H, Tobe T, Komiya A, Ichikawa T, Ito H: Aberrant expression of Pax-2 mRNA in renal cell carcinoma tissue and parenchyma of the affected kidney. Int J Urol 2001; 8: 60-64.
15. Gnarra JR, Dressler GR: Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides. Cancer Res 1995; 55: 4092-4098.
16. Fonsato V, Buttiglieri S, Deregibus MC, Puntorieri V, Bussolati B, Camussi G: Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am J Pathol 2006; 168: 706-713.
17. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK: PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009; 22: 1243-1250.
18. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK: PAX2 Expression in Ovarian Cancer. Int J Mol Sci 2013; 14: 6090-6105.
19. Kahraman K, Kiremitci S, Taskin S, Kankaya D, Sertcelik A, Ortac F: Expression pattern of PAX2 in hyperplastic and malignant endometrium. Arch Gynecol Obstet 2012; 286: 173-178.
20. Beauchemin D, Lacombe C, Van Themsche C: PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer 2011; 10: 148.
21. Zhang HS, Yan B, Li XB, Fan L, Zhang YF, Wu GH, Li M, Fang J: PAX2 protein induces expression of cyclin D1 through activating AP-1 protein and promotes proliferation of colon cancer cells. J Biol Chem 2012; 287: 44164-44172.
22. Ueda T, Ito S, Shiraishi T, Kulkarni P, Ueno A, Nakagawa H, Kimura Y, Hongo F, Kamoi K, Kawauchi A, Miki T: Hyper-expression of PAX2 in human metastatic prostate tumors and its role as a cancer promoter in an in vitro invasion model. Prostate 2014; 73: 1403-1412.
23. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR: Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003; 22: 7989-7997.
24. Li CG, Eccles MR: PAX Genes in Cancer; Friends or Foes? Front Genet 2012; 3: 6.
25. Liu P, Zhou J, Zhu H, Xie L, Wang F, Liu B, Shen W, Ye W, Xiang B, Zhu X, Shi R, Zhang S: VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine 2011; 55: 8-17.
26. Luo J, Zhou X, Ge X, Liu P, Cao J, Lu X, Ling Y, Zhang S: Upregulation of Ying Yang 1 (YY1) suppresses esophageal squamous cell carcinoma development through heme oxygenase-1. Cancer science 2013; 104: 1544-1551.
27. Yamasaki M, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y: Evaluation of the nodal status in the 7th edition of the UICC-TNM classification for esophageal squamous cell carcinoma: proposed modifications for improved survival stratification: impact of lymph node metastases on overall survival after esophagectomy. Ann Surg Oncol 2014; 21: 2850-2856
28. Zhang S, Lu J, Zhao X, Wu W, Wang H, Wu Q, Chen X, Fan W, Chen H, Wang F, Hu Z, Jin L, Wei Q, Shen H, Huang W, Lu D: A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. Carcinogenesis 2010; 31: 1251-1258.
29. Abbas T, Autta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
30. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM: p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002; 23: 1289-1296.
31. Lee EJ, Lee SJ, Kim S, Cho SC, Choi YH, Kim WJ, Moon SK: Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-kappaB/AP-1 pathway: involvement of the p21WAF1 expression. Cell Signal 2013; 25: 2025-2038.
32. Lee EJ, Park SS, Kim WJ, Moon SK: IL-5-induced migration via ERK1/2-mediated MMP-9 expression by inducing activation of NF-kappaB in HT1376 cells. Oncol Rep 2012; 28: 1084-1090.
33. Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild PJ, Sulser T, Schraml P, Moch H: Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. Clin Cancer Res 2009; 15: 3297-3304.
34. Powis G, Kirkpatrick L: Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654.
35. Wilso, M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, Rosato FS, Berger AC: Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res 2008; 146: 11-15.
36. Burger MC, Brucker DP, Baumgarten P, Ronellenfitsch MW, Wanka C, Hasselblatt M, Eccles MR, Klingebiel T, Weller M, Rieger J, Mittelbronn M, Steinbach JP: PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. Int J Oncol 2012; 41: 235-241.
37. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS: Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008: 456: 663-666.
38. Khoubehi B, Kessling AM, Adshead JM, Smith GL, Smith RD, Ogden CW: Expression of the developmental and oncogenic PAX2 gene in human prostate cancer. J Urol 2001; 165: 2115-2120.
39. Lee SB, Doberstein K, Baumgarten P, Wieland A, Ungerer C, Burger C, Hardt K, Boehncke WH, Pfeilschifter J, Mihic-Probst D, Mittelbronn M, Gutwein P: PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells. PloS one 2011; 6: e22312.
40. Adachi T, Alam R: The mechanism of IL-5 signal transduction. Am J Physiol 1998; 275: C623-633.
41. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, Komai-Koma M, Pitman N, Li Y, Niedbala W, McKenzie AN, Teixeira MM, Liew FY, Xu D: IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.